The Tresiba® FlexTouch® 100units/ml prefilled pens have been discontinued and have been out of stock since July 2023.

Actions for clinicians

• Do not initiate new patients on Tresiba® FlexTouch® 100units/ml pens.
• Consider prescribing Tresiba® Penfill® cartridges, taking into account the patient’s manual dexterity and ability to use the new device correctly.
• When prescribing Tresiba® Penfill® cartridges, ensure that the patient is prescribed a Novo Nordisk insulin delivery pen and appropriate needles.
• Seek advice from specialist diabetes teams on the use of an alternative insulin, if the above option is not considered suitable.
• Ensure that all patients initiated on a new device are counselled on the change in device, and provided with training on their use, including signposting to training videos as well as potential need for closer monitoring of blood glucose levels.

ScriptSwitch® messages have been enabled to provide information on this shortage to support primary care.

For detailed information on the shortage, refer to the Specialist Pharmacy Service Medicines Shortage Tool for actions required and supporting information.